Teva announces appointment of new global r&d and chief medical officer

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) announced today the appointment of eric a. hughes, md, phd as executive vice president, global r&d and chief medical officer. dr. hughes will begin his employment on august 1, 2022, and will be based out of teva's u.s. headquarters in parsippany, nj. dr. hughes joins teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as
TEVA Ratings Summary
TEVA Quant Ranking